Psychotropic drugs are commonly used in the elderly, and their use is associated with substantial morbidity due to drug toxicity and interactions. Toxicity occurs in part due to enhanced sensitivity to drugs in the elderly. Enhanced sensitivity has been reported for benzodiazepines, tricyclic antidepressants, opiates, barbiturates, caffeine, and antihistamines. Although for several drugs sensitivity appears to be due to pharmacokinetic factors, for most drug classes age-related kinetic changes are limited. Since most psychotropic agents interact with neurotransmitter receptors, it is likely that enhanced sensitivity to psychotropic drugs in the elderly is, at least in part, related to receptor interactions or post-receptor events. Prior studies indicate age-related changes in several neurotransmitter systems. To elucidate receptor contributions to enhanced drug sensitivity, we have chosen the benzodiazepine/GABA system as an initial model. Benzodiazepines are commonly used in the elderly and their use is associated with morbidity due to falls and cognitive impairment. Detailed pharmacokinetic studies indicate limited changes with age. Our initial findings indicate no significant age-related alterations in binding or function at the GABAA receptor complex in a mouse model. However, preliminary data indicate two potentially important neurochemical alterations in aged animals which may contribute to enhanced benzodiazepine sensitivity: 1. Decreased benzodiazepine receptor synthetic rate in aged mice; 2. Decreases in GABAA receptor gene expression in aged mice. Our major hypotheses are: 1. Aging is associated with alterations in benzodiazepine receptor synthetic rate and GABAA receptor gene expression; and 2. These alterations contribute to age-related differences in responses to chronic drug administration. Across a broad range of the animal lifespan, studies will examine benzodiazepine receptor synthetic rate and GABAA receptor gene expression in major brain regions and the effects of chronic benzodiazepine administration on GABAA receptor binding and function, benzodiazepine receptor synthetic rate and GABAA receptor gene expression. These studies will serve as a model for additional studies of other neurotransmitter systems; subsequent studies will examine the serotonergic system, and in particular effects of aging on 5HTlA receptor synthetic rate and on binding responses to chronic buspirone administration.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH047598-01
Application #
3387425
Study Section
Biochemical Endocrinology Study Section (BCE)
Project Start
1991-03-01
Project End
1994-02-28
Budget Start
1991-03-01
Budget End
1992-02-29
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Tufts University
Department
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02111
Koff, J M; Pritchard, G A; Greenblatt, D J et al. (1997) The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation. Pharmacology 55:217-27
Koff, J M; Miller, L G (1995) Prenatal lorazepam exposure: 4. Persistent alterations in pentylenetetrazole-induced seizure threshold and GABA-dependent chloride uptake after prenatal lorazepam exposure. Pharmacol Biochem Behav 51:721-4
Miller, L G; Koff, J M (1994) Interaction of central and peripheral benzodiazepine sites in benzodiazepine tolerance and discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 18:847-57
Kang, I; Lindquist, D G; Kinane, T B et al. (1994) Isolation and characterization of the promoter of the human GABAA receptor alpha 1 subunit gene. J Neurochem 62:1643-6
Byrnes, J J; Miller, L G; Greenblatt, D J et al. (1993) Chronic benzodiazepine administration. XII. Anticonvulsant cross-tolerance but distinct neurochemical effects of alprazolam and lorazepam. Psychopharmacology (Berl) 111:91-5
Byrnes, J J; Miller, L G; Perkins, K et al. (1993) Chronic benzodiazepine administration. XI. Concurrent administration of PK11195 attenuates lorazepam discontinuation effects. Neuropsychopharmacology 8:267-73
Lopez, F; Miller, L G; Greenblatt, D J et al. (1992) Chronic low-dose alprazolam augments gamma-aminobutyric acid(A) receptor function. J Clin Psychopharmacol 12:119-23
Byrnes, J J; Greenblatt, D J; Miller, L G (1992) Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone. Brain Res Bull 29:905-8
Miller, L G; Galpern, W R; Byrnes, J J et al. (1992) Chronic benzodiazepine administration. X. Concurrent administration of the peripheral-type benzodiazepine ligand PK11195 attenuates chronic effects of lorazepam. J Pharmacol Exp Ther 261:285-9
Miller, L G; Galpern, W R; Byrnes, J J et al. (1992) Benzodiazepine receptor binding of benzodiazepine hypnotics: receptor and ligand specificity. Pharmacol Biochem Behav 43:413-6